{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:53Z","timestamp":1788866933332,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcf.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T23:14:52Z","timestamp":1674170092000},"page":"722-729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Improved glucose tolerance after initiation of Elexacaftor \/ Tezacaftor \/ Ivacaftor in adults with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-2870","authenticated-orcid":false,"given":"Carolin","family":"Steinack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-7443","authenticated-orcid":false,"given":"Ren\u00e9","family":"Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-7566","authenticated-orcid":false,"given":"Mac\u00e9 M.","family":"Schuurmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9017-6143","authenticated-orcid":false,"given":"Thomas","family":"Gaisl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.jcf.2023.01.004_bib0001","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jcf.2023.01.004_bib0002","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2023.01.004_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jcf.2023.01.004_bib0004","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.004_bib0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The Extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jcf.2023.01.004_bib0006","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jpeds.2007.05.012","article-title":"Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes","volume":"151","author":"Elder","year":"2007","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.004_bib0007","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome","volume":"19","author":"Olesen","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.004_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2337\/dc09-1492","article-title":"Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain","volume":"33","author":"Hameed","year":"2010","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jcf.2023.01.004_bib0009","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpeds.2007.09.025","article-title":"Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis","volume":"152","author":"Bismuth","year":"2008","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.jcf.2023.01.004_bib0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ppul.1142","article-title":"Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis","volume":"32","author":"Koch","year":"2001","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2023.01.004_bib0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcf.2008.01.004","article-title":"Oxidative stress and cystic fibrosis-related diabetes: a pilot study in children","volume":"7","author":"Ntimbane","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2023.01.004_bib0012","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"10.1016\/j.jcf.2023.01.004_bib0013","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.004_bib0014","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2023.01.004_bib0015","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2023.01.004_bib0016","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"Suppl 27","key":"10.1016\/j.jcf.2023.01.004_bib0017","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/pedi.12732","article-title":"ISPAD Clinical Practice Consensus Guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents","volume":"19","author":"Moran","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"Pt 1","key":"10.1016\/j.jcf.2023.01.004_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1258\/000456307779596011","article-title":"Guidelines Development G. Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis","volume":"44","author":"Green","year":"2007","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"10.1016\/j.jcf.2023.01.004_bib0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcf.2015.03.001","article-title":"Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET)","volume":"15","author":"Coriati","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2023.01.004_bib0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jcf.2016.04.004","article-title":"Variation of glucose tolerance in adult patients with cystic fibrosis: what is the potential contribution of insulin sensitivity?","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2023.01.004_bib0021","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1464-5491.1995.tb00399.x","article-title":"The 30\u00a0min insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion","volume":"12","author":"Wareham","year":"1995","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/j.jcf.2023.01.004_bib0022","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jcf.2023.01.004_bib0023","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcf.2023.01.004_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of Elexacaftor\/Tezacaftor\/Ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcf.2023.01.004_bib0025","doi-asserted-by":"crossref","unstructured":"Modeling the Mean: Analyzing Response Profiles. Applied Longitudinal Analysis 2011. p. 105\u201341.","DOI":"10.1002\/9781119513469.ch5"},{"issue":"1","key":"10.1016\/j.jcf.2023.01.004_bib0026","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1378\/chest.13-2397","article-title":"Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease","volume":"146","author":"Barry","year":"2014","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jcf.2023.01.004_bib0027","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis-related diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcf.2023.01.004_bib0028","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"10","key":"10.1016\/j.jcf.2023.01.004_bib0029","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/en.2017-00187","article-title":"CFTR Influences Beta Cell Function and Insulin Secretion Through Non-Cell Autonomous Exocrine-Derived Factors","volume":"158","author":"Sun","year":"2017","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.004_bib0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2023.01.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112578","article-title":"High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study","volume":"9","author":"Scheuing","year":"2014","journal-title":"PLoS ONE"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:34:06Z","timestamp":1751582046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1569199323000061"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved glucose tolerance after initiation of Elexacaftor \/ Tezacaftor \/ Ivacaftor in adults with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}